Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Precision treatment significantly refines therapy outcomes for patients with HR+/HER2- breast cancer, enhancing effectiveness.
• Real-world data from a clinical cohort of patients indicates notable treatment response after multiple prior therapies.
• Analyzed treatments under a precision approach for patients in a metastatic setting, confirming improved patient management.
• Findings support the need for tailored treatment strategies rather than traditional one-size-fits-all approaches.